GlassScriptPhysician profile
Catherine S Mouzin
NPI 1073587341
$2,580.42
in general payments reported to CMS, 2019-2025
33 companies · $598 in 2025
The $598 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $537 · 2023: $439 · 2024: $474 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $393.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $270.09 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $232.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $174.23 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.37 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $135.51 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $123.28 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $119.96 | 2024-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $110.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $88.38 | 2021-2022 | |
| Lundbeck LLC | $72.69 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $72.53 | 2021-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $72.14 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Nestle Healthcare Nutrition INC. | $58.79 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.54 | 2021-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $41.79 | 2021 | |
| Pfizer INC. | $40.10 | 2021-2025 | |
| Eisai INC. | $32.76 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $32.56 | 2023-2024 | Ingrezza |
| Mylan Specialty L.P. | $31.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.33 | 2024-2025 | Jardiance |
| Abbott Laboratories | $27.87 | 2021-2022 | |
| Shield Therapeutics INC | $27.63 | 2022-2023 | Accrufer |
| Merck Sharp & Dohme LLC | $27.30 | 2021-2022 | |
| Corium, LLC | $23.30 | 2023 | Adlarity |
| Ardelyx, INC. | $19.49 | 2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $18.39 | 2025 | Uzedy |
| Exact Sciences Corporation | $17.34 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $16.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.73 | 2022 | |
| Alkermes, INC. | $14.34 | 2025 | Aristada, Lybalvi |
| Dexcom, INC. | $13.98 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $11.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Mouzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.